- Home
- SEZL vs PRCT Comparison
SEZL vs PRCT Comparison
Compare SEZL & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SEZL | PRCT |
|---|---|---|
| Founded | 2016 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Financial Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SEZL | PRCT |
|---|---|---|
| Price | $66.76 | $36.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $113.75 | $51.50 |
| AVG Volume (30 Days) | 966.4K | ★ 1.6M |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 104.61 | N/A |
| EPS | ★ 3.24 | N/A |
| Revenue | ★ $418,632,890.00 | $299,907,000.00 |
| Revenue This Year | $68.97 | $48.34 |
| Revenue Next Year | $26.02 | $29.35 |
| P/E Ratio | $21.70 | ★ N/A |
| Revenue Growth | ★ 88.74 | 50.07 |
| 52 Week Low | $24.86 | $27.80 |
| 52 Week High | $186.74 | $92.92 |
Technical Indicators
Market Signals| Indicator | SEZL | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 53.03 | 61.70 |
| Support Level | $66.72 | $33.27 |
| Resistance Level | $76.39 | $37.12 |
| Average True Range (ATR) | 4.18 | 1.87 |
| MACD | 1.61 | 0.64 |
| Stochastic Oscillator | 60.21 | 78.39 |
Price Performance
Historical ComparisonAbout SEZL Sezzle Inc.
Sezzle Inc is a financing institution that offers technology-driven payment platform. It allows customers to split their purchase into four installments and pay over 6 weeks with only the first payment due at the time of purchase. Companies operations comprise one reportable segment, the majority of which derives revenue from payment processing platform in North America.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.